Antipsychotic use in Parkinson’s disease: a single center retrospective chart review
Objective: To assess the prevalence of antipsychotic (AP) use in people with Parkinson’s disease (PwP), and identify factors associated with AP prescription and differences in…Longitudinal study of clinical symptoms associated with psychosis in Parkinson’s disease without dementia
Objective: Examine clinical features associated with psychosis among Parkinson’s disease (PD) patients without dementia. Background: Previously identified risk factors for PD psychosis include duration and…A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: To assess the effects of different doses of the metabotropic glutamate 2 and 3 (mGlu2/3) orthosteric antagonist (OA) LY-341,495 on the anti-dyskinetic and anti-psychotic…Evaluation of the effect of adding a mGlu2/3 orthosteric antagonist to a highly selective 5-HT2A antagonist on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To determine whether the therapeutic effect of serotonin 2A (5-HT2A) receptor antagonism on dyskinesia and psychosis may be reversed by orthosteric antagonism of metabotropic…Epidemiologic And Clinical Features Of Psychiatric Disorders In Patients With Parkinson’s Disease – A Retrospective Cohort Study
Objective: We aimed to assess the average duration of Parkinson's disease at the time patient was diagnosed with specific neuropsychiatric disturbance, to study their prevalence…Non-Invasive Brain Stimulation for the Treatment of Psychiatric Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis
Objective: This meta-analysis aims to assess the effect of NIBS technique for psychiatric symptoms in patients with PD. Background: Non-invasive brain stimulations (NIBS), especially repetitive…ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare beneficiaries
Objective: To examine health resource utilization (HRU) outcomes among PDP patients treated with PIMA vs. other AAPs. Background: Real-world analysis demonstrating pimavanserin (PIMA) benefits, the…Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management
Objective: Explore the relationship between multi-domain cognitive testing and patient-reported psychiatric symptoms in PwPD to self-medication management capabilities. Background: Parkinson’s disease (PD) is a complex…Phantom boarder syndrome associated with experimentally-induced presence hallucinations in Parkinson’s disease
Objective: Measuring experimentally-induced presence hallucinations in patients with Parkinson’s disease phantom boarder phenomena. Background: Phantom boarder syndrome (PB) is described as the sensation that someone…Reduced Risk of Mortality and Antipsychotics in Parkinson’s Disease-Related Psychosis: Pimavanserin vs Off-Label Antipsychotics
Objective: Summarize the available data for the mortality risk associated with Parkinson’s disease (PD) psychosis (PDP) and pimavanserin. Background: PDP is associated with increased mortality…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »